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DObjective: This propensity-matched study compared clinical and echocardiographic outcomes between patients
undergoing transcatheter aortic valve implantation (TAVI) and sutureless aortic valve replacement.
Methods: From January 2010 to March 2012, 122 patients (age 79.4  5.3 years, logistic euroSCORE
12%  8.4%) underwent minimally invasive sutureless aortic valve replacement, and 122 (age
84.6 6.2 years, logistic euroSCORE 20.9% 2.5%) underwent TAVI. After propensity matching, 37matched
pairs were available for analysis.
Results: Preoperative characteristics and risk scores of matched groups were comparable. In-hospital
mortalities were 0% in the sutureless group and 8.1% (n ¼ 3) in the TAVI group (P ¼ .24). Permanent
pacemaker implantation was required in 4 patients in the sutureless group and 1 patient in the TAVI group
(10.8% vs 2.7%; P ¼ .18). A neurologic event was recorded in 2 patients of each group. Predischarge
echocardiographic data showed higher paravalvular leak rate in the TAVI group (13.5% vs 0%; P ¼ .027).
At mean follow-up of 18.9  10.1 months, overall cumulative survival was 91.9% and significantly differed
between groups (sutureless 97.3% vs TAVI 86.5%; P ¼ .015). In the TAVI group, a significant difference in
mortality was observed between patients with (n ¼ 20) and without (n ¼ 17) paravalvular leak (25% vs 0%;
P ¼ .036).
Conclusions: Combining the advantage of standard diseased valve removal with shorter procedural times,
minimally invasive sutureless aortic valve replacement may be the first-line treatment for high-risk
patients considered in the ‘‘gray zone’’ between TAVI and conventional surgery. (J Thorac Cardiovasc Surg
2014;147:561-7)According to the recent guidelines of the European Society
of Cardiology on the management of valvular heart
disease,1 aortic valve replacement (AVR) is recommended
as first-line therapy in patients with severe symptomatic
aortic valve stenosis to improve both symptoms and
survival. In the last few years, in particular after the
publication of the Cohort A results of the PARTNER
(Placement of AoRTic TraNscathetER Valve) trial,2 there
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The Journal of Thoracic and Castrategies such as transcatheter aortic valve implantation
(TAVI) for high-risk patients with symptomatic severe
aortic valve stenosis. From the dualism between the surgical
and transcatheter approaches, a new option has emerged:
recent studies have demonstrated better clinical and
cosmetic results with minimally invasive techniques for
AVR versus conventional surgery.3 The drawback of
minimally invasive surgery is that it generally requires
longer crossclamp and operative times. This may expose
patients to potential additive risks, especially if the
procedure is performed by surgeons who are not experts
or are still on the learning curve. Although there are no
data supporting this observation, a high level of surgical
skills is required for these procedures because of the
increasing use of technology, and a learning curve is
unavoidable. More recently, sutureless AVR devices have
been developed that enable short procedural times and
also easy implantation of the aortic valve prosthesis when
using a minimally invasive surgical approach.4-7 In case
of the Perceval S (Sorin Group Srl, Saluggia, Italy), this
hybrid solution is somewhere between conventional
surgical AVR, as it allows removal of the native diseased
valve, and the transcatheter approach, as the bioprosthetic
valve is mounted on an expandable stent fixed to therdiovascular Surgery c Volume 147, Number 2 561
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
CABG ¼ coronary artery bypass grafting
CORONARY ¼ Coronary Artery Bypass Surgery
Off- or On-Pump Revascularization
Study
PARTNER ¼ Placement of AoRTic
TraNscathetER Valve [trial]
TAVI ¼ transcatheter aortic valve
implantation
TRITON ¼ Surgical Treatment of Aortic
Stenosis With a Next Generation
Surgical Aortic Valve [trial]
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Daortic annulus without sutures. Although follow-up data are
relatively short term, this implantation technique is reported
to be associated with very short procedural times.8
The aim of this single-center study was to assess
retrospectively and compare all consecutive patients who
have undergone TAVI or minimally invasive sutureless
AVR in the last 2 years at our Center, after careful
evaluation by our multidisciplinary heart team including
cardiologists, cardiac surgeons, and cardiac anesthesio-
logists. A propensity score analysis was used to create
matched pairs comparable for perioperative risk.MATERIALS AND METHODS
We collected data of all patients with the diagnosis of severe aortic valve
stenosis with an indication for surgery in our center since 2010.
Two specific programs were initiated in our institution at the same time:
the first program was developed in collaboration between cardiologists
and cardiac surgeons for the use of TAVI (Sapien and Sapien XT; Edwards
Lifesciences Inc, Irvine Calif), whereas the second program involved use of
the Perceval S sutureless prosthesis. Every week, during an interdepart-
mental conference, we evaluated all patients affected by severe aortic valve
stenosis referred to our center from peripheral hospitals, private practices,
or our emergency department, considering comorbidities and surgical risk
to determine the best therapy. In all patients aged older than 65 years
with an indication for isolated AVR considered candidates for surgery
(irrespective of euroSCORE), a low frailty score (evaluated by clinical
inspection and other factors not included in the euroSCORE or Society
of Thoracic Surgeons scoring system, such as poor mobility, nonvascular
degenerative neurologic diseases including Parkinson and Alzheimer
diseases, home oxygen therapy, liver cirrhosis), and compatible
echocardiographic findings (symmetric aortic annulus with a diameter
19-27 mm and a sinotubular junction/annulus ratio <1.3), a Perceval
S sutureless valve was implanted earlier as part of a premarket study
(Cavalier Study) and later (after European Community approval in 2011)
as routine use. During the premarket study, patients also signed an
additional informed consent for the experimental use of the new type of
prosthesis (not yet CE mark approved). An informed consent for the use
of personal data and follow-up contact was also signed by all patients.
The study was approved by the local ethics committee.
All patients with frailty factors judged at very high surgical risk or with
a logistic euroSCORE greater than 20% underwent a TAVI procedure as
part of a multicenter registry (Source XT) for the use of the Sapien XT
prosthesis. The transfemoral approach was considered as the first-line562 The Journal of Thoracic and Cardiovascular Surgstrategy, leaving the transapical approach in case of inadequate vascular
access. Patients assigned to the TAVI strategy with concomitant coronary
artery disease underwent coronary angioplasty with stent implantation
before TAVI if the coronary anatomy seemed favorable. Conversely,
patients with unsuitable coronary anatomy underwent combined sutureless
AVR and coronary artery bypass grafting (CABG), except for 1 patient with
isolated ostial right coronary artery lesion who underwent transaortic TAVI
and off-pump CABG (Table 1).9 Patients with a bicuspid aortic valve were
excluded from both sutureless and TAVI implantation.
After 2 years of extensive experience with both procedures, a total of
244 patients were operated on, equally distributed between the TAVI and
sutureless groups (n¼ 122 each). Patients of both groups were comparable
for clinical and surgical characteristics, and a retrospective propensity
score analysis was performed. For the matched pair samples, postoperative
and follow-up clinical and echocardiographic data were obtained.
All patients were followed up at our outpatient clinic and were evaluated
clinically and by questionnaire to assess events between visits.
In particular, the need for rehospitalization for cardiovascular of other
causes was recorded. Prosthetic valve function was evaluated with
transthoracic echocardiography. The presence of paravalvular regurgitation
was defined according to current guidelines as none or trace, mild,
moderate, or severe.10 All echocardiographic examinations were
performed by either of 2 echocardiographists with a Philips iE33
ultrasound machine (Philips, Eindhoven, The Netherlands).
The Perceval implantation technique has been described previously.11
If associated CABG surgery had to be performed, distal coronary
anastomoses preceded prosthesis implantation, and proximal surgical
sutures either were performed during primary crossclamping, after
tangential clamping of the ascending aorta, or were avoided completely
if suitable. General anesthesia with endotracheal intubation was used in
both groups. Our heart team prefers this technique because it allows
performance of intraoperative transesophageal echocardiography. In
patients undergoing TAVI by the transfemoral route, the endotracheal
tube was removed immediately after the procedure if appropriate. In all
other cases, patients were extubated in the intensive care unit. Transfemoral
procedures were performed through a minimally invasive direct vascular
access: the access site was chosen according to computed tomographic
findings, size of the common femoral artery, amount of calcification of
the vessel and iliac arteries, and tortuosity, or in selected cases with the
Prostar percutaneous closure device (Abbott Vascular, Santa Clara, Calif).
Before all TAVI procedures, the cardiac apex and intended optimal coaxial
alignment were localized by transthoracic echocardiography. The surgical
technique for positioning and deploying the Sapien XT valve prosthesis has
been well described and standardized for both the transapical and
transfemoral approaches.12,13Statistical Analysis
Categoric variables were summarized as frequencies (%), and
continuous variables were summarized as mean  SD. A propensity score
matching (1:1) was performed to control selection bias as a result of
nonrandom assignment to the groups. The propensity score was defined
as the probability of receiving TAVI. This was estimated by means of a
multivariate regression analysis. The following patient characteristics
and major preoperative risk factors were entered into the model: age,
sex, body surface area, logistic euroSCORE, previous cardiac surgery,
hypertension, hyperlipidemia, left ventricular ejection fraction, renal
disease, previous myocardial infarction, chronic obstructive pulmonary
disease, peripheral vascular disease, and New York Heart Association
functional class. Once the propensity score had been estimated for each
subject, a receiver operating characteristic curve area proved the perfor-
mance of the model (Figure 1). The P value of the Hosmer-Lemeshow
test was .016, and C statistic for the fitted logistic regression model was
0.8 (P<.001), indicating that the model fitting was excellent. Pairs were
generated with the 5:1 digit matching approach.ery c February 2014
TABLE 1. Preoperative characteristics of the study population
Variable
Sutureless





Age (y) 79.5  5.4 84.7  6.2 <.001
Male sex 55 (45.1%) 49 (40.2%) .259
BSA (m2) 1.8  0.21 1.7  0.16 <.001
Diabetes 31 (25.4%) 49 (40.2%) .013
NYHA functional class 2.9  0.4 3.0  0.5 .052
Renal insufficiency 18 (14.7%) 20 (16.4%) .537
Logistic euroSCORE (%) 12  8.4 20.9  2.5 .031
Previous cardiac surgery 15 (12.3%) 23 (18.9%) .108
LVEF (%) 57.3  7.9 56.3  14.9 .497
Pulmonary hypertension 23 (18.8%) 47 (38.5%) .001
AS 104 (85.25%) 110 (90.16%)
Combined AS and AR 18 (14.75%) 12 (9.84%)
Associated CABG 43 (35.2%) 1 (0.8%) .001
Surgical approach
Full sternotomy 46 (37.7%)
Partial sternotomy 73 (59.8%)




Prosthesis size (mm) 24.0  1.3 24.8  1.9 <.001
Crossclamp time (min) 43.3  18.4
CPB time (min) 73.4  23.1
Data are mean  SD or number and percentage. AVR, Aortic valve replacement;
TAVI, transcatheter aortic valve implantation; BSA, body surface area; NYHA, New
York Heart Association; LVEF, left ventricular ejection fraction; AS, aortic stenosis;
AR, aortic regurgitation; CABG, coronary artery bypass grafting; CPB, cardiopulmo-
nary bypass.
TABLE 2. Preoperative characteristics of the matched sutureless and
transcatheter aortic valve implantation groups
Variable
Sutureless





Age (y) 81.5  5.1 84.5  5.1 .06
Male sex 15 (40.5) 18 (48.6%) .32
BSA (m2) 1.7  0.2 1.8  0.18 .3
Logistic euroSCORE (%) 18.1  1.9 20.6  2.2 .81
Redo procedure 8 (21.6%) 8 (21.6%) .61
Hypertension 27 (73%) 22 (59.5%) .16
Hyperlipidemia 13 (35.1%) 17 (45.9%) .24
LVEF (%) 55.3  9.3 55.4  14.6 .98
Renal insufficiency 5 (13.5%) 5 (13.5%) .61
Previous myocardial infarction 10 (27%) 14 (37.8%) .23
COPD 7 (18.9%) 12 (32.4%) .14
Peripheral vascular disease 5 (13.5%) 4 (10.8%) .5
NYHA functional class 2.97  0.5 3.16  0.5 .13
Data are mean  SD or number and percentage. AVR, Aortic valve replacement;
TAVI, transcatheter aortic valve implantation; BSA, body surface area; LVEF, left
ventricular ejection fraction; COPD, chronic obstructive pulmonary disease;
NYHA, New York Heart Association.
Santarpino et al Acquired Cardiovascular Disease
A
C
DFinally, postoperative outcomes of the resulting 37 matched pairs of
both groups (TAVI and sutureless) with the same propensity score were
compared, including in-hospital and valve-related complications and
survival. Normal distribution of data was assessed with the Shapiro-Wilk
test. Continuous variables were compared by paired t test and categoricFIGURE 1. Receiver operating characteristic curve.
The Journal of Thoracic and Cavariables by c2 test. Cumulative survival curves were computed
according to the Kaplan-Meier method. Survival curves and freedom
from valve-related complications were compared with a Cox proportional
hazards model stratified for the matched pairs.
RESULTS
Preoperative clinical and echocardiographic characteris-
tics of the overall study population are reported in Table 1.
Four patients underwent percutaneous transluminal
coronary angioplasty with stent implantation before the
TAVI procedure. Patients of the TAVI group were
significantly older, had lower body surface area, and more
often had diabetes or pulmonary hypertension. A higher
proportion of patients in the sutureless group underwent
associated CABG surgery, and they received a larger
mean size prosthesis.
After propensity matching, 37 matched pairs were
available for analysis. Preoperative clinical and echocardio-
graphic characteristics of all matched pairs are reported
in Table 2. Six patients in the TAVI matched group had
undergone previous CABG surgery, and 1 had undergone
percutaneous transluminal coronary angioplasty before
the procedure. Two patients in the sutureless matched group
had previously undergone CABG surgery. Eight patients in
both groups underwent redo surgery. In the sutureless
group, cardiopulmonary bypass and aortic crossclamping
times were 68.9  20.2 min and 38.9  13.7 min,
respectively.
Postoperative outcomes are reported in Table 3. Although
both groups had comparable body surface areas (Table 2), a
larger prosthesis size was used in the TAVI group than in the
sutureless group (25.3  2.1 vs 24.2  1.13 mm; P ¼ .015).
Despite this, no differences in postoperative mean transaortic
gradient were observed (14.2  5.8 vs 13.3  3.9 mm Hg;rdiovascular Surgery c Volume 147, Number 2 563
TABLE 3. Postoperative outcomes of the matched sutureless and
transcatheter aortic valve implantation groups
Variable
Sutureless





In-hospital mortality 0 3 (8.1%) .24
ARF requiring CVVH 0 2 (5.4%) .25
Stroke 2 (5.4%) 2 (5.4%) >.999
Permanent PM implantation 4 (10.8%) 1 (2.7%) .18
Mean transaortic gradient (mm Hg) 13.3  3.9 14.2  5.8 .564
AR at discharge (at least mild) 0 5 (13.5%) .027
AVR, Aortic valve replacement; TAVI, transcatheter aortic valve implantation;
ARF, acute renal failure; CVVH, continuous venovenous hemofiltration;
PM, pacemaker; AR, aortic regurgitation.
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DP ¼ .564). At discharge, the incidence of aortic regurgitation
caused by postprocedural paravalvular leakage was higher in
the TAVI group than in the sutureless group (13.5% vs 0%;
P ¼ .027).
Intraoperative complications occurred in 4 patients of
the TAVI group (conversion to surgery with full
sternotomy and conventional AVR as a result of valve
dislocation in 2, and need for mechanical resuscitation
or emergency coronary stenting in 1 each) and in 3
patients of the sutureless group (1 bleeding requiring
conversion to full sternotomy, 1 prosthesis explantation
because of malpositioning with implantation of a stented
prosthesis, and 1 postoperative bleeding necessitating
reexploration; P ¼ .5). Despite conversion, these patients
were considered to be part of the original group enrolled
and were included in the follow-up analysis. Three
in-hospital deaths occurred in the TAVI group: of these,
1 was of septic shock and 2 of multiorgan failure (caused
by liver insufficiency in 1 case and by respiratory
insufficiency in the other). Permanent pacemaker
implantation was required in 4 patients of the
sutureless matched group and in 1 patient of the TAVI
matched group (10.8% vs 2.7%; P ¼ .18).
At a mean follow-up of 18.9  10.1 months, the
cumulative survival was 91.9% (Figure 2), with a
significant difference between groups (sutureless vs TAVI,
97.3% vs 86.5%; P ¼ .015). In the TAVI group, a
significant difference in the mortality at follow-up was
observed between patients with (n ¼ 20) and without
(n ¼ 17) paravalvular leak (25% vs 0%; P ¼ .036).
When comparing the survival in the sutureless group
(n ¼ 37, 97.3%) with that of patients with no paravalvular
leak in the TAVI group (n ¼ 17, 100%), no significant
differences were seen.
The cumulative freedom from rehospitalization was
70.3% (86.5% in the sutureless group and 54.1% in the
TAVI group; P ¼ .054). The overall freedom from
neurologic events was 94.6% (97.3% in the sutureless
group and 91.9% in the TAVI group; P ¼ .236). There
was a trend toward a higher rate of neurologic events in564 The Journal of Thoracic and Cardiovascular Surgthe TAVI group, although this did not reach statistical
significance.
DISCUSSION
Our study compared 2 groups of patients undergoing
sutureless AVR versus TAVI who were operated on by
the same surgical team for both procedures. A propensity-
matched analysis was used to generate 2 homogeneous
groups with respect to preoperative characteristics and
surgical risk. Our findings demonstrate that minimally
invasive surgery is associated with similar in-hospital
outcomes but lower paravalvular leak and mortality than
is TAVI. In addition, the lower rate of postoperative
paravalvular leak seems to result in a higher freedom
from rehospitalization.
In the PARTNER trial, paravalvular regurgitation was
more frequent after TAVI and was associated with increased
late mortality.14 A significant difference in the 2-year
mortality was reported between patients with mild to
severe paravalvular leak and patients without or with only
trace paravalvular leak. Notably, paravalvular aortic
regurgitation occurred in approximately 40% of patients.
In our study population, paravalvular leakage was common
in the TAVI group and was associated with increased
mortality and rehospitalization rate during follow-up
relative to patients with no or minimal leakage or to those
who had undergone sutureless AVR.
Conventional surgical AVR is associated with reduced
rates of paravalvular regurgitation. In the study of Sponga
and colleagues,15 4.2% of patients were found to have
paravalvular leak, and long-term survival was more
negatively affected by the presence of significant residual
aortic regurgitation (1/4 grade).
From a theoretic point of view, the sutureless valve
implantation technique might be expected to be associated
with higher rates of paravalvular leakage because of the
absence of active fixation of the prosthetic valve to the
native aortic annulus. Previous studies on sutureless aortic
valves, however, showed very low rates of paravalvular
leakage, which were similar to the reported rates observed
with standard models. In a multicenter study including
patients from 10 European referral centers, sutureless
AVR with the Enable bioprosthesis (Medtronic, Inc,
Minneapolis, Minn) was associated with a 2.1% rate of
major paravalvular leaks [4]. More recently, in the
TRITON study,5 the 1-year clinical outcome of AVR with
the sutureless Edwards Intuity prosthesis demonstrated a
paravalvular leak rate of 2.3% (1.4% and 0.9% for
early and late occurrences, respectively). The Perceval
S sutureless bioprosthesis, which we adopted, overall
showed a slightly worse performance relative to other
models. In a series of high-risk patients who received a
Perceval bioprosthesis in 2 European centers, 9 patients
(4%) required reoperation for paravalvular regurgitationery c February 2014
FIGURE 2. Kaplan-Meier survival curve. TAVI, Transcatheter aortic
valve implantation; Cum, cumulative.
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Dduring follow-up.6 D’Onofrio and associates16 compared
clinical and echocardiographic outcomes of patients
undergoing transapical implantation of a Sapien prosthesis
with those of patients undergoing AVR with the sutureless
Perceval S aortic valve. Although data showed that the
rate of paravalvular leak was greater in the TAVI group, it
was as high as 15.8% in the AVR group.
After propensity score matching, no patient in our AVR
group demonstrated paravalvular leak; however, the rate
of paravalvular leak reached 1.6% (n¼ 2) when the overall
group of 122 patients in the sutureless group was consid-
ered. The main reason for the remarkable difference be-
tween our findings and those of D’Onofrio and
associates16 and the Paris and Hannover experience6 may
be related to the aortic valve and annulus decalcification
technique. As recommended by the manufacturer, the
Perceval S requires no aggressive decalcification of the
native valve, which is left in situ (similar to a TAVI proce-
dure), and only excess calcific debris that would result in
asymmetric annular dilatation is removed. In the 2 previ-
ously mentioned studies, it seems that the aortic annulus
was only mildly decalcified. With the exception of the
very first cases, a moderate decalcification of the aortic
annulus is performed routinely at our center. At this stage,
however, any hypothesis regarding the effect of decalcifica-
tion on residual paravalvular leakage remains speculative,
and other factors may play a significant role (eg, asymmetric
bicuspid aortic valve). Notwithstanding this, moderate
decalcification resulted in low rates of paravalvular leakage,
and thus better long-term outcomes, in our study patients. A
larger prosthesis size, however, was used in the TAVI group
than in the sutureless group. It is well known that prosthesis
size is not directly comparable across manufacturers, evenThe Journal of Thoracic and Cain cases of equivalent nominal size. In addition, both Sapien
and Perceval are self-expanding prostheses, and accurate
measurement of diameter thus is not feasible. In this respect,
measurement of the effective orifice area or the mean trans-
aortic gradient may bemore reliable, as evidenced by lack of
differences in postoperative transaortic gradient reported in
our study (14.2 5.8 vs 13.3 3.9 mm Hg; P¼ .564). Not
surprisingly, the manufacturer of the Perceval S no longer
provides prosthesis size in millimeters but marks them as
small, medium, large, and extra large.
A direct comparison between conventional surgical AVR
and TAVI was performed in cohort A of the PARTNER
study.2 No definitive data regarding the indications for
conventional AVR or TAVI in high-risk patients could be
derived, however, also because of the intrinsic limitations
that exist in sponsored research studies. In addition, the non-
inferiority statistical approach and the intention-to-treat
analysis included patients who refused the surgical option,
thus affecting the results of treatment outcome. Accord-
ingly, further studies are warranted to clarify this topic.
Several investigations have also directly or indirectly shown
the superiority of the minimally invasive approach relative
to conventional surgical AVR. In the study by Johnston
and coworkers,3 aortic valve surgery through an upper J ster-
notomy not only had cosmetic advantages relative to full
sternotomy but also improved respiratory mechanics. Iso-
lated AVR can also be performed through an anterolateral
thoracotomy, which does not require a standard full incision
and does not interrupt the osseous continuity of the chest, al-
lowing even better respiratory mechanics. Glauber and col-
leagues17 compared this approach with standard median
sternotomy by means of a propensity score analysis and
showed that avoiding median sternotomy improves the clin-
ical outcome, with lower incidences of postoperative atrial
fibrillation and blood transfusion and shorter ventilation
time and hospital stay. The policy at our institution is to
perform isolated AVR through a minimally invasive
approach routinely with a J sternotomy or anterolateral tho-
racotomy according to the position of the ascending aorta at
the level of the pulmonary artery bifurcation on chest
computed tomography.18 Whether this surgical strategy
has a favorable impact on clinical outcome as compared to
TAVI remains to be clearly elucidated; it goes beyond the
scope of this study.
In their comparative study of TAVI versus minimally
invasive Perceval implantation with propensity score
matching, D’Onofrio and associates16 included only
patients undergoing TAVI through a transapical approach.
As may be inferred from the discussion at the 92nd
American Association for Thoracic Surgery annual
meeting, the reasons for this patient selection are related
to the fact that data regarding transfemoral TAVI were
collected by cardiologists rather than by cardiac surgeons.
We do agree with those authors on the need for studiesrdiovascular Surgery c Volume 147, Number 2 565
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Devaluating the ‘‘gray zone’’ of patients for whom the indica-
tions for TAVI versus surgical AVR is still unclear, but we
also believe that all TAVI approaches should be assessed
as a whole to be much closer to ‘‘real world’’ patient popu-
lations. Accordingly, in our study no patients were excluded
from propensity score matching: the TAVI group included
patients who had undergone a transcatheter procedure for
AVR through either transfemoral or transapical access,
transaortic TAVI with associated CABG, or valve-in-valve
implantation in the aortic position. Only patients undergo-
ing valve-in-valve implantation in the mitral position were
excluded. The sutureless group included patients who had
undergone minimally invasive AVR either isolated or asso-
ciated with CABG through a full sternotomy. We also
included patients who had undergone combined CABG
and Perceval S implantation, because it is likely that with
the use of a heart team approach the feasibility of transaortic
TAVI associated with on- or off-pump CABG will be
considered increasingly often. Although few data in the
literature are available except for isolated case reports,19
this option seems a valid alternative within the development
of a hybrid revascularization program,20 allowing perfor-
mance of TAVI and myocardial revascularization without
cardiopulmonary bypass in the growing population of
patients with aortic valve disease associated with coronary
artery disease (coexisting in as many as 75% of patients
according to the Dallas group21).
Current recommendations suggest performance of
associated CABG only in patients undergoing conventional
surgical AVR, whereas TAVI should be considered in
patients at high risk (Society of Thoracic Surgeons score>8)
orwith prohibitive surgical risk but favorablevalve anatomy.22
The major interest in the TAVI procedure is based on the
possibility of avoiding cardiopulmonary bypass. It is well
known that removal of the diseased valve—infeasible with
the transcatheter approach—results in lower rates of
paravalvular leak, which is likely among the major
determinants of stroke after TAVI. No evidence so far,
however, supports the hypothesis that avoidance of
cardiopulmonary bypass confers any benefits. A similar
debate is currently taking place regarding the use of
off-pump versus on-pump CABG. The results of the ongoing
CORONARY (Coronary Artery Bypass Surgery Off- or On-
Pump Revascularization Study) trial will clarify these issues.
A few years ago, the same lively debate surrounded the initial
enthusiasm for coronary stents, which were supposed to
replace cardiac surgery in the near future; however, current
data still strongly support cardiac surgery.23
Study Limitations
Propensity score matching has allowed comparison
between groups without differences in the distribution of
preoperative characteristics, but at the expense of the
sample size (only 37 patients for each group). This is the566 The Journal of Thoracic and Cardiovascular Surgmost important limitation of our study. The decision to
proceed with surgical AVR or TAVI was based on the
clinical judgment of the heart team, because this
multidisciplinary approach is key to procedural success,
and on the evaluation of the frailty score by clinical
inspection. Our propensity score was based on traditional
risk factors, and frailty was not considered in the pair
matching because it could represent a potential bias.
In 2010, the TAVI and sutureless programs were initiated
simultaneously at our institution, and the different learning
curves associated with the techniques may have played a
role. Although the difference is difficult to quantify,
especially in relatively small sample sizes, we might
speculate that in the setting of a cardiac surgical team the
learning curve was faster and easier for sutureless AVR
than for TAVI. Sutureless AVR is quite similar to
conventional surgical AVR, whereas TAVI is a more
difficult procedure that requires a longer learning curve.
Both types of surgical procedure were performed with the
assistance of a proctor, however, who left our center only
after the learning curve was completed.
Different surgical access routes were used in the study
groups (full sternotomy and J ministernotomy for sutureless
AVR and transfemoral and transapical approaches for
TAVI). The small sample size, however, did not allow
subgroup analysis.
Finally, the relatively short follow-up (mean 18 months)
represents another study limitation.
CONCLUSIONS
In conclusion, removal of the diseased native valve may
enhance procedural quality by avoiding paravalvular leak.
In combination with minimally invasive sutureless AVR,
this may become the first-line treatment for high-risk
patients considered in the gray zone between TAVI
and conventional surgery. Further larger, prospective,
randomized studies are warranted to confirm our results.
The authors thank Joachim Schidt, MD, and Ferdinand Vogt,
MD, for their support in performing the echocardiographic
examinations.
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